Angiogenic factors and use thereof in treating cardiovascular disease
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 24, 2003
Grant Date -
N/A
app pub date -
Mar 11, 1998
filing date -
Sep 6, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to novel VEGF protein products, and nucleic acids encoding these novel protein products, comprising exons 1-6 and 8 of the VEGF gene, and derivatives thereof, and these uses in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF.sub.145 and its derivatives have been found to be active mitogens for vascular endothelial cells and to function as angiogenic factors in-vivo. VEGF.sub.145 and its derivatives have novel properties compared with previously characterized VEGF species with respect to cellular distribution, susceptibility to oxidative damage, and extra-cellular matrix (ECM) binding ability. The present invention also relates to derivatives of VEGF.sub.145 which have altered properties in that they have altered biological activity and altered heparin-binding activity when compared to VEGF.sub.145. The present invention provides methods of treating the cardiovascular system, enhancing endothelialization of diseased vessels, and enhancing drug permeation by providing the novel VEGF protein products. The invention also provides expression vectors, compositions, and kits for use in the methods of the invention.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully